Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675011 · ClinicalTrials.gov registry record · NA
Embozene Microspheres for Uterine Fibroid Embolization (UFE)
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT01675011 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 4 participants.
The verdict
NCT01675011, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a randomized, prospective, multi-center study of 225 female subjects age 30-50 years with symptoms from uterine fibroids. All subjects will be followed for a total of thirty-six (36) months following uterine fibroid embolization.
Interventions
- DEVICE Embozene® Microspheres
- DEVICE Embosphere®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01675011
The ClinicalTrials.gov registry entry for NCT01675011 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Embozene® Microspheres is the first listed.
NCT01675011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01675011 about?
NCT01675011 is a clinical study titled "Embozene Microspheres for Uterine Fibroid Embolization (UFE)". This is a randomized, prospective, multi-center study of 225 female subjects age 30-50 years with symptoms from uterine fibroids. All subjects will be followed for a total of thirty-six (36) months following uterine fibroid embolization.
What is the current status of trial NCT01675011?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2012-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01675011?
The interventions under investigation include: Embozene® Microspheres (DEVICE), Embosphere® (DEVICE).
Who is sponsoring clinical trial NCT01675011?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.